603079 圣达生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.7612.339-4.1872.3785.772
总资产报酬率 ROA (%)2.7131.679-3.2041.8414.372
投入资产回报率 ROIC (%)2.9621.846-3.5562.0664.950

边际利润分析
销售毛利率 (%)26.03421.26516.01017.72928.929
营业利润率 (%)11.6285.628-6.2794.89810.313
息税前利润/营业总收入 (%)10.7984.753-7.6631.98411.258
净利润/营业总收入 (%)9.4534.503-7.4514.1249.094

收益指标分析
经营活动净收益/利润总额(%)91.695106.6503.55882.77873.789
价值变动净收益/利润总额(%)1.8391.476-0.89728.45626.924
营业外收支净额/利润总额(%)-0.1955.132-0.8131.027-1.752

偿债能力分析
流动比率 (X)4.4052.8192.3532.6412.227
速动比率 (X)3.5112.0341.5791.6531.689
资产负债率 (%)25.26028.08126.12818.83624.243
带息债务/全部投入资本 (%)19.93120.55819.8268.13515.698
股东权益/带息债务 (%)397.061380.705401.2801,115.623530.845
股东权益/负债合计 (%)290.621251.494279.317425.938308.636
利息保障倍数 (X)-13.374-4.0315.341-0.66910.025

营运能力分析
应收账款周转天数 (天)62.68155.16261.62864.09655.515
存货周转天数 (天)115.283117.711153.364152.423125.083